What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Omixon Celebrates a Successful EFI 2015

EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more

By kriszta.katona 0 comments

Whole-Gene Next-Generation Sequencing of HLA Genes Reveals Hidden Diversity of Intronic Regions

Authors: György Horváth, Krisztina Rigó, Tim Hague, Szilveszter Juhos Introduction: Intronic regions of HLA alleles are less studied, but with the help of modern NGS kits covering whole genes it is easier to investigate this relatively unknown domain of sequences. To reveal …more

By kriszta.katona 0 comments